Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

07/05/2024 - Annual General Meeting

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

44.64 USD

Average target price

53.76 USD

Spread / Average Target

+20.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.36%	90.49B
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 30/04/2024 BST			5-day change	1st Jan Change
43.94 ^USD	-1.57%		-10.31%	-14.36%

04-30	Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...
04-30	A flurry of corporate results ahead of the Fed's rate decision

Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	04-30
A flurry of corporate results ahead of the Fed's rate decision	04-30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	04-30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	04-30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	04-30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	04-29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	04-29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	04-29	MT
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	04-29	CI
S&P 500 Q1 earnings estimated growth improves; stocks up for week	04-26	RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	04-26	MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating	04-26	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51	04-26	MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65	04-26	MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy	04-26	MT
Bristol Myers: positive opinion from the CHMP for Opdivo	04-26	CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer	04-26	DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40	04-26	MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating	04-26	MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55	04-26	MT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	04-26	CI
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	04-25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	04-25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	04-25	MT
Sector Update: Health Care	04-25	MT